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Introduction
Hematopoietic stem and progenitor cell (HSPC) transplantation 
is the paradigmatic stem cell therapy, with ~50,000 transplants 
performed worldwide per year to treat a variety of blood disorders 
(1). Despite its curative potential, difficulties in obtaining suffi-
cient numbers of HLA-matched HSPCs contribute to poor trans-
plantation outcomes and limit broader applicability. Derivation 
of large quantities of HSPCs from human pluripotent stem cells 
(PSCs), including embryonic stem cells (ESCs) and/or induced 
pluripotent stem cells (iPSCs), holds great promise to mitigate 
many HSPC transplantation–related limitations. However, despite 
much progress, generation of fully functional and engraftment- 
competent HSPCs from human pluripotent stem cells ex vivo has 
remained challenging (2).
“Bone marrow homing” refers to the process by which HSPCs 
transit from the bloodstream to the bone marrow (BM). This pro-
cess, which is a prerequisite for functional hematopoiesis, involves 
two components: (1) trafficking of circulating HSPCs to special-
ized BM endothelial beds and (2) extravasation of HSPCs at those 
beds. Homing involves a multistep cascade that begins with the 
tethering and rolling of transplanted cells on discrete BM sinusoi-
dal vessels that is mediated by interactions between E-selectin on 
endothelial cells and its ligands on HSPCs. Once cells have migrat-
ed to relevant sinusoids, extravasation ensues as integrins (princi-
pally VLA-4) become activated via chemokines by binding to their 
receptors (e.g., SDF-1 [also known as CXCL12] binding to CXCR4) 
to induce firm adherence of HSPCs to the endothelial wall. Final-
ly, cells undergo transendothelial migration and parenchymal 
lodgment, processes modulated by chemokine gradients within 
the BM (3). Although BM homing is a critical aspect of HSPC biolo-
gy, studies assessing the homing properties of HSPCs from human 
pluripotent stem cells are lacking (2).
In this study, we examined the expression and function of mol-
ecules that mediate HSPC homing to BM and identified a marked 
deficiency of E-selectin ligands on the surface of PSC-derived 
HSPCs. We also demonstrate a simple and potent strategy to create 
functional E-selectin ligands on the surface of iPSC-derived HSPCs 
using modified mRNA encoding the glycosyltransferase fucosyl-
transferase 6 (FUT6). The glycoengineered human iPSC-derived 
HSPCs exhibited markedly enhanced tethering and rolling inter-
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activity that was completely blocked by the CXCR4 antagonist 
AMD3100 (Figure 1B). We next assessed expression of the inte-
grin subunits that constitute VLA-4 and VLA-5, as VLA-4 is criti-
cal for HSPC extravasation, and both VLA-4 and VLA-5 mediate 
binding to fibronectin, a key mediator of HSPC lodgment. hiPS-
HSPCs expressed robust levels of the VLA-4 integrin subunits α4 
and β1, and moderate expression of α5 (Figure 1C), which together 
with β1, constitutes VLA-5 (9). Integrin dimers are known to exist 
in three distinct conformations: bent-closed (inactive), extended- 
closed (primed), and extended-open (active) (10). Activation of 
integrins, canonically by CXCR4 engagement (SDF-1–induced 
signaling), is critical to enabling their function as mediators of 
homing and marrow lodgment (11). To assess the integrin activa-
tion status of hiPS-HSPCs at baseline and in response to SDF-1, 
we used activation-specific antibodies to the integrin β1 subunit, 
which is common to both VLA-4 and VLA-5 (Figure 1D). This 
analysis revealed that hiPS-HSPCs natively display β1 integrins in 
an extended-closed (primed) conformation. Furthermore, the β1 
integrins were converted to the extended-open (active) conforma-
tion via SDF-1–induced signaling, to levels comparable to that of 
cells exposed to manganese, a strong signaling-independent inte-
grin activator (Figure 1D). Collectively, these data indicate that 
hiPS-HSPCs express appreciable levels of CD44, CXCR4, VLA-4, 
and VLA-5, and that these mediators of extravasation and lodg-
ment function normally in these cells.
Next, we analyzed E-selectin ligand expression using 
HECA452, an antibody that detects a tetrasaccharide glycan 
known as sialyl Lewis X (sLex), the canonical E-selectin ligand 
binding determinant (12). Strikingly, the hiPS-HSPCs had very 
low sLex expression compared with control peripheral blood 
actions with endothelial cells under shear stress conditions in vitro 
and displayed increased homing and extravasation into the calvar-
ial BM of immunocompromised mice in vivo.
Results and Discussion
Building upon previously reported protocols (4–6), we developed 
a serum-free, stromal cell–free differentiation protocol capable of 
generating high percentages of hematopoietic cells from a human 
iPSC line derived using modified mRNA (Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI92030DS1) (7). By day 10 of differentiation, 
round, refractile, non-adherent hematopoietic cells were observed 
above the adherent cell layer (Supplemental Figure 1B) and corre-
sponded with the expression of hematopoietic progenitor markers 
(Supplemental Figure 1, C and D). Hematopoietic differentiation 
was similarly highly efficient across multiple human PSC lines, 
including two ESC lines and iPSCs derived from a patient with 
Pearson’s syndrome (Supplemental Figure 1E). Consistent with 
their acquisition of primitive hematopoietic markers, the human 
iPSC-derived hematopoietic cells possessed robust progenitor 
activity (Supplemental Figure 1, F and G), and we termed these 
cells human iPSC-derived HSPCs (hiPS-HSPCs).
We then proceeded to examine on hiPS-HSPCs the molecules 
known to mediate BM extravasation, and marrow lodgment, of 
human HSPCs. First, we assessed expression of the SDF-1 recep-
tor CXCR4 and the hyaluronan receptor CD44 (8) and observed 
that hiPS-HSPCs expressed moderate to high levels of these mole-
cules (Figure 1A). Function of CXCR4 was confirmed by transwell 
migration assays, where hiPS-HSPCs demonstrated significantly 
increased transmigration activity toward an SDF-1 gradient, an 
Figure 1. hiPS-HSPCs possess molecules that mediate extravasation. (A) Representative histograms showing expression of CXCR4 and CD44 on hiPS-
HSPCs and control RPMI8402 cells. (B) Normalized transmigration activity of hiPS-HSPCs and control human PBMCs in response to SDF-1. CXCR4 antag-
onist (AMD3100) used to confirm migration was CXCR4-mediated. n = 3. (C) Representative histograms showing expression of β1, α4, α5 integrin subunits 
on hiPS-HSPCs and Jurkat control cells. (D) β1 integrin activation status of hiPS-HSPCs stimulated with SDF-1 or MnCl2 from multiple experiments. 4B4, all 
β1 conformations; N29, primed β1 conformation; HUTS4, active β1 conformation. n = 4–6; **P < 0.01, ***P < 0.001; NS, not significant by 1-way ANOVA with 
Tukey’s HSD test. Error bars indicate SEM.
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2C). Since sLex-bearing glycoproteins are specifically known to 
play a critical role in cellular trafficking, FUT6 modified mRNA 
was utilized for all further experiments. FUT6 modified mRNA 
transfection consistently and robustly increased sLex expression 
of hiPS-HSPCs in multiple independent experiments (Supplemen-
tal Figure 2E). Time course analysis of FUT6 modified mRNA– 
transfected hiPS-HSPCs showed that sLex expression peaked 
between 24 and 72 hours after transfection and decreased there-
after (Supplemental Figure 2F). No detrimental effects on hema-
topoietic differentiation or colony-forming activity were observed 
(Supplemental Figure 2, G–I). Collectively, these data indicate that 
FUT6 modified mRNA transfection is an effective strategy for 
generating E-selectin ligands on hiPS-HSPCs.
To determine whether the increased sLex and E-selectin–Ig 
reactivity corresponds to functional E-selectin binding activity, 
we tested the ability of FUT6 modified mRNA–transfected hiPS-
HSPCs to tether and roll under fluid shear conditions on TNF-α–
activated HUVEC monolayers using a parallel plate flow cham-
ber. FUT6 modified mRNA–transfected hiPS-HSPCs showed 
increasingly higher numbers of rolling cells with increasing shear 
stress, in contrast to control cells, which maintained uniformly 
low levels of rolling cells (Figure 2D and Supplemental Video 1). 
Furthermore, rolling velocities were significantly lower in FUT6 
modified mRNA–transfected hiPS-HSPCs, indicative of increased 
E-selectin ligand binding (Figure 2E). Blocking E-selectin or 
mononuclear cells (PBMCs) (Figure 2A). To determine whether 
this low sLex expression was differentiation protocol– or cell line– 
specific, we assessed sLex expression on HSPCS derived from 
iPSCs according to two alternative published protocols (6, 13), 
as well as HSPCs derived from two different ESC lines. Gating 
on putative HSPCs as described in the respective published pro-
tocols (Supplemental Figure 2A), we observed similarly low sLex 
levels of the populations examined (Supplemental Figure 2, B 
and C). The lack of E-selectin ligand expression led us to hypoth-
esize that increasing E-selectin ligand expression might result in 
increased homing of these cells upon transplantation. Based on 
earlier experiments in other cell types (14), we predicted that hiPS-
HSPCs could express sLex upon fucosylation with α(1,3)-fucosyl-
transferase. We therefore generated modified mRNAs (7) encod-
ing 3 human α(1,3) fucosyltransferases (hereafter referred to as 
FUT3, FUT6, and FUT7 modified mRNAs; Supplemental Figure 
2D) and transfected them into hiPS-HSPCs (Supplemental Figure 
3). Total cell surface sLex expression was markedly increased in 
hiPS-HSPCs transfected with modified mRNAs encoding FUT6 
and FUT7, but not FUT3 (Figure 2B). To specifically visualize 
E-selectin binding glycoproteins, we performed Western blot 
analysis using an E-selectin–Ig chimera as a probe (Figure 2C). 
FUT6 modified mRNA–transfected hiPS-HSPCs had higher levels 
of E-selectin binding glycoproteins than FUT3 modified mRNA–, 
FUT7 modified mRNA–, or mock-transfected hiPS-HSPCs (Figure 
Figure 2. FUT6 modified mRNA–mediated glycoengineering enhances tethering and rolling of hiPS-HSPCs on endothelial cells under shear conditions. 
(A) Representative histograms showing expression of sLex on hiPS-HSPCs and PBMC control cells measured by HECA452 antibody. (B) Representative 
histograms showing expression of sLex on hiPS-HSPCs 24 hours after transfection with modified mRNAs encoding FUT3, FUT6, and FUT7. (C) Western 
blot with an E-selectin–Ig chimera or β-actin (loading control) on lysates of hiPS-HSPCs cells mock transfected or transfected with the indicated modified 
mRNAs 2 days earlier. (D) Quantitation of E-selectin–mediated rolling of control or FUT6 modified mRNA–transfected hiPS-HSPCs on TNF-α–activated 
HUVECs under increasing shear stress. E-selectin blocking antibody reduces rolling to baseline, while no interaction was observed on HUVECs not activated 
with TNF-α. n = 3. (E) FUT6 modified mRNA–transfected hiPS-HSPCs exhibit reduced rolling velocities on TNF-α–activated HUVECs. n = 3. Error bars indi-
cate SEM. *P < 0.05, **P < 0.01 by Student’s t test.
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sel 24 hours after transplant (Figure 3D). These studies revealed 
that FUT6 modified mRNA–transfected hiPS-HSPCs had sig-
nificantly increased extravasation frequency compared with co- 
transplanted control-treated cells (Figure 3E). To establish the 
absolute homing efficiency of FUT6 modified mRNA–transfected 
hiPS-HSPCs, we performed short-term BM homing experiments, 
comparing FUT6 modified mRNA–transfected hiPS-HSPCs with 
CD34+ cells from mobilized peripheral blood (CD34+ mPB cells) 
(Supplemental Figure 4, A and B). Despite the improved hom-
ing and transmigration engendered by the creation of functional 
E-selectin ligands, FUT6 modified mRNA–transfected hiPS-
HSPCs still showed 5-fold lower BM homing efficiency compared 
with CD34+ mPB  cells (Supplemental Figure 4, A and B). To deter-
mine whether the increased BM homing of the modified cells was 
sufficient to enable hematopoietic engraftment, we injected con-
trol or FUT6 modified mRNA–transfected hiPS-HSPCs into NSG 
mice. Mice transplanted with control-transfected hiPS-HSPCs did 
not show detectable human engraftment (Figure 3, F and G). In 
contrast, a subset of mice receiving transplant of FUT6 modified 
mRNA–transfected hiPS-HSPCs exhibited low human chimerism 
in the peripheral blood at 2 weeks after transplant (Figure 3, F and 
withholding TNF-α activation decreased the numbers of rolling 
FUT6 modified mRNA–transfected cells, confirming that their 
altered rolling properties are mediated exclusively by increased 
E-selectin ligand activity (Figure 2D and Supplemental Video 2). 
These data show that FUT6 modified mRNA glycoengineering 
generates functional E-selectin ligands on hiPS-HSPCs, and 
mediates increased tethering and rolling interactions on acti-
vated endothelium.
To determine whether the increased E-selectin ligand expres-
sion engendered by FUT6 modified mRNA is functionally rel-
evant in vivo, we assessed BM homing of hiPS-HSPCs in vivo 
using calvarial BM imaging (Figure 3). Control or FUT6 modified 
mRNA–transfected hiPS-HSPCs stained with DiI or DiD were 
coinjected into NSG mice, and calvaria were imaged using intra-
vital microscopy to measure BM homing (Figure 3, A–C). Imaging 
and enumeration of labeled cells 2 hours after transplant showed 
that the FUT6 modified mRNA–transfected hiPS-HSPCs exhib-
ited a significant increase in homing compared with control- 
transfected cells (Figure 3C). Extravasation was assessed by label-
ing blood vessels with a vascular imaging dye and quantifying the 
number of hiPS-HSPCs that had migrated out of the blood ves-
Figure 3. FUT6 modified mRNA enhances BM homing and 
extravasation of xenotransplanted hiPS-HSPCs. (A) Dye- 
labeled FUT6- (DiD, blue) or control modified mRNA– 
transfected (DiI, green) hiPS-HSPCs mixed at a 1:1 ratio and 
imaged before transplant. (B) 3D reconstruction of a calvar-
ium section of an NSG mouse transplanted with DiD- and 
DiI-labeled hiPS-HSPCs. Image represents view of sagittal 
plane, with a portion of bone digitally removed to optimize 
visualization. Imaging depth extends to approximately 150 
μm beneath the bone. (C) FUT6 modified mRNA–transfected 
hiPS-HSPCs showed increased homing at 2 hours after trans-
plant compared with control modified mRNA–transfected 
cells. n = 3 independent experiments (6 mice). (D) Image taken 
24 hours after transplant showing DiD- (blue) and DiI-labeled 
(green) hiPS-HSPCs and AngioSense-labeled blood vessels 
(red). Extravasated hiPS-HSPCs were defined as those com-
pletely distinct from the blood vessel. White arrows indicate 
non-extravasated cells; yellow arrows indicate extravasated 
cells. (E) FUT6 modified mRNA transfection increases the 
percentage of homed hiPS-HSPCs that extravasated from the 
calvarial blood vessels. n = 3 independent experiments  
(5 mice). (F) Representative FACS plots showing human 
chimerism at 2 weeks after transplant. (G) Time course of 
peripheral blood chimerism in NSG mice receiving transplant 
of human CD34+ cord blood (CB) cells, and control or FUT6 
modified mRNA–transfected hiPS-HPCs. Scale bars: 50 μm. 
Error bars in C and E indicate SEM. P values in C and E were 
calculated by Student’s t test.
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ered within the context of future efforts focused on generating 
functional HSPCs from human PSCs.
Methods
Details about experimental procedures are provided in Supple-
mental Methods.
Statistics. P values were calculated using a 1-way ANOVA with 
Tukey’s honest significant difference (HSD) or Student’s t test as indicat-
ed in the figure legends. Student’s t test was 2-tailed. A P value less than 
0.05 considered significant, and all data are reported as mean ± SEM.
Study approval. All animal use was in accordance with the guide-
lines of the Animal Care and Use Committee of the University of 
Massachusetts Medical School and The Jackson Laboratory. Human 
cord blood and PBMCs from peripheral blood draws were collected 
in heparin from healthy volunteers under signed informed consent in 
accordance with the Declaration of Helsinki and with approval from 
the Institutional Review Board of University of Massachusetts Medi-
cal School or Brigham and Women’s Hospital, respectively.
Author contributions
JML, BD, JAS, RS, and DJR designed experiments; JML, BD, JAS, 
and LLK performed experiments and analyzed data; and JML, BD, 
JAS, LLK, DLG, LDS, MAB, CPL, RS, and DJR wrote the manuscript.
Acknowledgments
This work was supported by grants from the NIH (R01HL107630, 
U01HL107440, U01HL099997, and 1UC4DK104218, and 
U19HL129903 to DJR; OD018259 to MAB, DLG, and LDS; 
EB017274 and HL97794 to CPL; and P01-HL107146 to RS), the 
Jane Brock-Wilson Fund (to DJR), Google Inc. (to DJR), the Leona 
M. and Harry B. Helmsley Charitable Trust (to DJR, MAB, DLG, 
and LDS), Team Jobie Fund (to RS), the New York Stem Cell Foun-
dation (to DJR), and the American Federation for Aging (to DJR).
Address correspondence to: Derrick J. Rossi, Warren Alpert Build-
ing, Room #149e, 200 Longwood Avenue, Boston, Massachu-
setts 02115, USA. Phone: 617.713.8900; E-mail: derrick.rossi@ 
childrens.harvard.edu.
G). However, human chimerism decreased over time and was no 
longer detectable 8 weeks after transplant (Figure 3, F and G).
In the present study, we focused on BM homing, a previ-
ously unaddressed aspect for deriving engraftment-competent 
hiPS-HSPCs. We report that molecular determinants of extrav-
asation are intact in hiPS-HSPCs, but hiPS-HSPCs are deficient 
in expression of E-selectin ligands. To overcome this deficiency, 
we developed a simple modified mRNA–based approach to tem-
porarily increase the E-selectin ligands on these cells, resulting 
in increased tethering/rolling in vitro, and improved calvarial 
homing and extravasation in vivo. We anticipate that strategies to 
increase E-selectin ligand expression could be applicable as part 
of a multifaceted approach to optimize the production of HSPCs 
from human PSCs. As an example of the power of glycoengineer-
ing to enforce E-selectin ligand expression, fucosylation of human 
cord blood using recombinant fucosyltransferase has recently 
been reported to accelerate engraftment in xenotransplant mod-
els (15, 16) and has also shown promising results in early-stage 
clinical trials (17). 
It should be noted that in this study, increasing homing and 
extravasation by FUT6 modified mRNA was not sufficient to 
generate long-term engraftable hiPS-HSPCs. Additional func-
tional deficiencies (unrelated to homing) likely exist and must 
be overcome before fully engraftable HSPCs from human PSCs 
can be generated. One promising strategy that we are pursuing 
is the use of modified mRNA to transiently increase expression 
of relevant transcription factors. Since several modified mRNAs 
encoding different proteins can be introduced simultaneous-
ly (7), a combinatorial modified mRNA transfection approach 
could be a powerful strategy to generate fully functional human 
PSC–derived HSPCs. Importantly, since modified mRNA is 
non-permanent and non-genome-integrative, it is particular-
ly amenable to clinical use. In conclusion, we have identified 
E-selectin ligand deficiency as an important factor limiting the 
BM homing ability of hiPS-HSPCs and provide evidence that a 
modified mRNA–based glycoengineering strategy can overcome 
this deficiency. Importantly, our findings suggest that glycoengi-
neering to enforce E-selectin ligand expression could be consid-
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